Mast Cell Cytokines IL-1, IL-33, and IL-36 Mediate Skin Inflammation in Psoriasis: A Novel Therapeutic Approach with the Anti-Inflammatory Cytokines IL-37, IL-38, and IL-1Ra.
IL-1
IL-1Ra
IL-37
IL-38
cytokine
immunology
inflammation
mast cell
psoriasis
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
28 Jul 2021
28 Jul 2021
Historique:
received:
24
06
2021
revised:
22
07
2021
accepted:
25
07
2021
entrez:
7
8
2021
pubmed:
8
8
2021
medline:
9
9
2021
Statut:
epublish
Résumé
Psoriasis (PS) is a skin disease with autoimmune features mediated by immune cells, which typically presents inflammatory erythematous plaques, and is associated with many comorbidities. PS exhibits excessive keratinocyte proliferation, and a high number of immune cells, including macrophages, neutrophils, Th1 and Th17 lymphocytes, and mast cells (MCs). MCs are of hematopoietic origin, derived from bone marrow cells, which migrate, mature, and reside in vascularized tissues. They can be activated by antigen-provoking overexpression of proinflammatory cytokines, and release a number of mediators including interleukin (IL)-1 and IL-33. IL-1, released by activated keratinocytes and MCs, stimulates skin macrophages to release IL-36-a powerful proinflammatory IL-1 family member. IL-36 mediates both innate and adaptive immunity, including chronic proinflammatory diseases such as psoriasis. Suppression of IL-36 could result in a dramatic improvement in the treatment of psoriasis. IL-36 is inhibited by IL-36Ra, which binds to IL-36 receptor ligands, but suppression can also occur by binding IL-38 to the IL-36 receptor (IL-36R). IL-38 specifically binds only to IL-36R, and inhibits human mononuclear cells stimulated with IL-36 in vitro, sharing the effect with IL-36Ra. Here, we report that inflammation in psoriasis is mediated by IL-1 generated by MCs-a process that activates macrophages to secrete proinflammatory IL-36 inhibited by IL-38. IL-37 belongs to the IL-1 family, and broadly suppresses innate inflammation via IL-1 inhibition. IL-37, in murine models of inflammatory arthritis, causes the suppression of joint inflammation through the inhibition of IL-1. Therefore, it is pertinent to think that IL-37 can play an inhibitory role in inflammatory psoriasis. In this article, we confirm that IL-38 and IL-37 cytokines emerge as inhibitors of inflammation in psoriasis, and hold promise as an innovative therapeutic tool.
Identifiants
pubmed: 34360845
pii: ijms22158076
doi: 10.3390/ijms22158076
pmc: PMC8348737
pii:
doi:
Substances chimiques
IL-38 protein, human
0
IL37 protein, human
0
Interleukin 1 Receptor Antagonist Protein
0
Interleukin-1
0
Interleukin-33
0
Interleukins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
J Exp Med. 2007 Oct 29;204(11):2603-14
pubmed: 17908936
Nat Immunol. 2011 Oct 19;12(11):1035-44
pubmed: 22012443
Int J Mol Sci. 2019 Jul 05;20(13):
pubmed: 31284527
JAMA Dermatol. 2016 Jul 1;152(7):825-8
pubmed: 27096382
J Invest Dermatol. 2007 Jun;127(6):1292-308
pubmed: 17429444
J Biol Regul Homeost Agents. 2019 May-Jun;33(3):669-673
pubmed: 31195792
Dermatol Ther. 2020 Jan;33(1):e13191
pubmed: 31837249
J Biol Regul Homeost Agents. 2019 Jun 11;33(3):657-659
pubmed: 31184097
J Biol Regul Homeost Agents. 2020 Sep 18;34(5):1629-1632
pubmed: 32945158
J Biol Regul Homeost Agents. 2019 Sep-Oct;33(5):1321-1326
pubmed: 31663301
Int J Mol Sci. 2019 Mar 13;20(6):
pubmed: 30871134
Dermatol Ther. 2019 Jul;32(4):e12943
pubmed: 31012218
N Engl J Med. 2009 Jul 30;361(5):496-509
pubmed: 19641206
Nat Rev Rheumatol. 2019 Jul;15(7):386
pubmed: 31164736
Front Immunol. 2018 Jul 06;9:1549
pubmed: 30034395
Front Cell Neurosci. 2019 Aug 02;13:353
pubmed: 31427928
Curr Opin Rheumatol. 2017 Mar;29(2):208-213
pubmed: 27926540
Br J Dermatol. 2012 Oct;167(4):717-24
pubmed: 22716185
Nat Immunol. 2010 Nov;11(11):973
pubmed: 20959797
Annu Rev Immunol. 2005;23:749-86
pubmed: 15771585
Exp Dermatol. 2004 Apr;13(4):193-222
pubmed: 15086336
Immunity. 2013 Dec 12;39(6):1003-18
pubmed: 24332029
Yale J Biol Med. 1986 Mar-Apr;59(2):97-106
pubmed: 3488622
Eur J Pharmacol. 2018 Jan 5;818:294-299
pubmed: 28970014
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3001-5
pubmed: 22315422
Cell Death Dis. 2018 Oct 30;9(11):1104
pubmed: 30377293
J Biol Regul Homeost Agents. 2020 Mar-Apr;34(2):319-326
pubmed: 32431140
Immunity. 2019 Apr 16;50(4):778-795
pubmed: 30995499
Case Reports Immunol. 2019 Aug 4;2019:1902817
pubmed: 31467740
Curr Allergy Asthma Rep. 2020 Jun 12;20(8):40
pubmed: 32533268
Blood. 2011 Nov 24;118(22):5813-23
pubmed: 21860022
Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):E9381-E9390
pubmed: 30232261
J Pharmacol Exp Ther. 2015 Jul;354(1):24-31
pubmed: 25906776
Circulation. 1999 Apr 27;99(16):2079-84
pubmed: 10217645
Arch Dermatol Res. 2012 Aug;304(6):443-9
pubmed: 22438166
Immunol Rev. 2018 Jan;281(1):179-190
pubmed: 29247987
Int J Immunopathol Pharmacol. 2013 Oct-Dec;26(4):855-9
pubmed: 24355220
Immunol Rev. 2018 Jan;281(1):8-27
pubmed: 29247995
J Dent Res. 2020 Dec;99(13):1425-1434
pubmed: 32758110
J Allergy Clin Immunol. 2017 Aug;140(2):335-348
pubmed: 28780941
Biomed Pharmacother. 2020 Feb;122:109705
pubmed: 31918276
Rheumatology (Oxford). 2016 Dec;55(12):2220-2229
pubmed: 27567100
Semin Nephrol. 2007 Jan;27(1):98-114
pubmed: 17336692
J Biol Regul Homeost Agents. 2019 Apr 04;33(2):469-475
pubmed: 30945511
Arthritis Rheum. 2010 Feb;62(2):430-40
pubmed: 20112373
Proc Natl Acad Sci U S A. 2019 Oct 22;116(43):21659-21665
pubmed: 31591201
Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):10088-10093
pubmed: 30224457
J Biol Regul Homeost Agents. 2019 Jul 22;33(4):1227-1232
pubmed: 31332984
Immunobiology. 2016 Feb;221(2):182-7
pubmed: 26454413
Semin Immunol. 2013 Dec 15;25(6):389-93
pubmed: 24275600
N Engl J Med. 2017 Mar 9;376(10):957-970
pubmed: 28273019
Nat Immunol. 2019 Nov;20(11):1435-1443
pubmed: 31591569
Clin Exp Immunol. 1995 May;100(2):306-13
pubmed: 7743670
Joint Bone Spine. 2013 Oct;80(5):449-53
pubmed: 23849463
N Engl J Med. 2012 Mar 29;366(13):1251-2
pubmed: 22455420
Proc Natl Acad Sci U S A. 2019 Oct 8;116(41):20500-20504
pubmed: 31548430
Front Immunol. 2019 May 24;10:1162
pubmed: 31191535
Immunol Rev. 2018 Jan;281(1):5-7
pubmed: 29248001
Eur J Dermatol. 2010 Nov-Dec;20(6):865-7
pubmed: 21047723
J Biol Regul Homeost Agents. 2019 Jul-Aug;33(4):1019-1022
pubmed: 31347346
J Biol Regul Homeost Agents. 2020 Aug 03;34(5):1623-1627
pubmed: 32744052
Immunol Rev. 2018 Jan;281(1):154-168
pubmed: 29247993
Trends Pharmacol Sci. 2004 Nov;25(11):563-8
pubmed: 15491778
J Allergy Clin Immunol. 2011 Mar;127(3):787-94.e1-9
pubmed: 21377044
J Invest Dermatol. 1989 Feb;92(2):235-9
pubmed: 2783951
J Biol Regul Homeost Agents. 2019 Jan 18;33(1):1-6
pubmed: 30656901
Nat Immunol. 2010 Nov;11(11):1014-22
pubmed: 20935647
Immunol Rev. 2018 Jan;281(1):191-196
pubmed: 29247986
Methods Mol Biol. 2011;677:207-20
pubmed: 20941613
Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Oct;1864(10):1338-1349
pubmed: 31125703
J Stroke Cerebrovasc Dis. 2009 Jul-Aug;18(4):269-76
pubmed: 19560680
Semin Immunol. 2013 Dec 15;25(6):469-84
pubmed: 24275598
Clin Exp Dermatol. 1996 Sep;21(5):325-9
pubmed: 9136148
Front Immunol. 2018 Mar 01;9:407
pubmed: 29545809
Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4448-53
pubmed: 20160089
J Dermatol Sci. 2008 Jan;49(1):7-19
pubmed: 18024086
Curr Opin Pharmacol. 2012 Aug;12(4):486-90
pubmed: 22398321
Clin Rev Allergy Immunol. 2018 Dec;55(3):295-311
pubmed: 28780731
J Invest Dermatol. 2011 Dec;131(12):2428-37
pubmed: 21881584
Nat Rev Rheumatol. 2019 Oct;15(10):612-632
pubmed: 31515542
Neuroimmunomodulation. 1995 Jul-Aug;2(4):241-8
pubmed: 8963753
Proc Natl Acad Sci U S A. 2017 May 16;114(20):E4002-E4009
pubmed: 28461492